P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition

Clopidogrel, a P2Y12 inhibitor, is a novel anti -fibrosis agent for chronic kidney disease (CKD), but its mechanisms remain unclear, which we investigated by silencing P2Y12 or treating unilateral ureteral obstruction (UUO) in LysM-Cre/Rosa To-mato mice with clopidogrel in vivo and in vitro. We found that P2Y12 was significantly increased and correlated with progressive renal fibrosis in CKD patients and UUO mice. Phenotypically, up to 82% of P2Y12-expressing cells within the fibrosing kidney were of macrophage origin, identified by co-expressing CD68/F4/80 antigens or a macrophage-lineage -tracing marker Tomato. Unexpectedly, more than 90% of P2Y12-expressing macrophages were undergoing macro-phage-to-myofibroblast transition (MMT) by co-expressing alpha smooth muscle actin (a-SMA), which was also confirmed by single-cell RNA sequencing. Functionally, clopidogrel improved the decline rate of the estimated glomerular filtration rate (eGFR) in patients with CKD and significantly inhibited renal fibrosis in UUO mice. Mechanistically, P2Y12 expression was induced by transforming growth factor 01 (TGF-01) and promoted MMT via the Smad3-dependent mechanism. Thus, silencing or pharmacological inhibition of P2Y12 was capable of inhibiting TGF-0/Smad3-mediated MMT and progressive renal fibrosis in vivo and in vitro. In conclusion, P2Y12 is high-ly expressed by macrophages in fibrosing kidneys and mediates renal fibrosis by promoting MMT via TGF-0/Smad3 signaling. Thus, P2Y12 inhibitor maybe a novel and effective anti -fibrosis agent for CKD.